

Provided by:



Bonner Conference Division of Hematopathology Multi-Institutional

Bonner Conference Division of Hematopathology Multi-Institutional Conference 2026-2027 - 7/22/2026

July 22, 2026

5:00 PM - 6:00 PM

Virtual through Zoom and in person

Target Audience

This program has been designed for PATHOLOGY - CLINICAL, PATHOLOGY - ANATOMIC, PATHOLOGY - Cytopathology, PATHOLOGY - Dermatopathology, PATHOLOGY - Hematopathology, PATHOLOGY - Pathology-Medical Microbiology, PATHOLOGY - Pathology-Molecular Genetic, PATHOLOGY - Pediatric, PATHOLOGY-ANATOMIC/PATHOLOGY-CLINICAL

Series Educational Objectives

After participating in this regularly scheduled series, participants should be able to:

- 1 Discuss diagnostic features and challenges in hematopathology diseases using a case-based approach
- 2 Discuss basic concepts and controversies in Hematopathology and allied fields (hematology/oncology, flow cytometry, molecular diagnostics, cytogenetics) and discuss how to apply recently published data to these cases
- 3 Discuss how to Integrate emerging diagnostic testing modalities in Hematopathology

Accreditation

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit:

Physicians: Penn Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: This activity is not approved for nursing contact hours

Pharmacists: This activity is not approved for pharmacy contact hours.

PAs: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of **1.00** Category 1 credits for completing this activity.

Approved for (PSRM) patient safety/risk management designation

Acknowledgement of Commercial Support*: None

For more information, please contact
Josette Tyson, Karla Robinson, Lissette Maisonet, Francisca Wilson Dean
(215) 614-0978, (215) 615-4773, (215) 662-6550, (215) 662-6550
josette.tyson@penntmedicine.upenn.edu, Karla.Robinson@Pennmedicine.upenn.edu,
lissm@upenn.edu, franwd@upenn.edu

Check your transcript online at <https://upenn.cloud-cme.com>

Disclosure of Relevant Financial Relationships and Unapproved Uses of Products

It is policy at Penn Medicine Office of Continuing Medical and Interprofessional Education for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships (RFRs) that they have with any ineligible company, which is defined as any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Disclosure to learners includes all RFRs for all those in control of content including faculty, planners, moderators, and reviewers.

The intent of this policy is to ensure that Penn CME/CE certified activities promote quality and safety, are effective in improving medical practice, are evidence-based, are based on valid content, and are independent of control from ineligible companies and free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure information was found to contain any financial relationships. Part of the peer review process involved reviewing the content, determining which financial relationships were relevant, and applying appropriate mitigation strategies. In addition, all faculty were instructed to provide balanced, scientifically rigorous and evidence-based presentations.

The staff in the Office of Continuing Medical and Interprofessional Education (CME and IPCE), have disclosed that they have no financial relationships with any ineligible companies. Any peer reviewer who is determined to have a relevant financial relationship must recuse themselves from the peer review process.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|-----------------------------|--------------------------------------|--|
| Siddharth Bhattacharyya, MD | Co-Director | Nothing to disclose - 05/04/2026 |
| Giby George, MD | Other Planning Committee Member | Nothing to disclose - 12/10/2025 |
| Dana Martin, MD | Co-Director, Faculty | Nothing to disclose - 06/10/2026 |
| Pichayut Nithagon, MD | Other Planning Committee Member | Nothing to disclose - 09/04/2025 |
| Mohamed Omer, MBBS | Other Planning Committee Member | Nothing to disclose - 07/23/2025 |
| Jeffrey R Ordner III, DO | Other Planning Committee Member | Nothing to disclose - 07/23/2025 |

Relevant financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected